CALGB CLOSED PROTOCOLS: |
| NOTICE: The
following is a listing of CALGB closed protocols that contain
pathology components. This is to be used as a reference and
should not replace the required material contained within the
protocol. |
|
|
BREAST: |
- 9343: Lump & Tam+/- RT in node (-) Br Ca Pts >70 (E9343, RTOG 97-02) (Closed Effective 02/26/1999)
- 9394: Adj CX AC vs Seq AC, High Risk, node (-) (SWOG 9313) (Closed Effective 05/01/1997)
- 9443: Adj therapy w/ Tam v Tam +HRP, post men, + nodes (EB193) (Closed Effective 11/01/1999)
- 9484: Linkage Mol & Epid Br Ca Invest.: Spec Registry (Closed Effective 09/01/1999)
- 9640: Intergroup 4+ Node ABMT Breast Ca Trial (S9623) (Closed Effective 02/15/2001)
- 9741: A-T-C vs AC-T q2 or 3 wks in Node+ Breast Ca (Closed Effective 03/31/1999)
- 49802: AT vs AC for Adj Tx of Node+/Hi Risk Node- (E2197) (Closed Effective 01/21/2000)
- 49806: Eval of Novel Therapeutic Agents in St IV Breast Ca (Closed Effective 02/28/2002)
- 49808: Neoadj 4AC -> Weekly Taxol w/wo Herceptin St III (Closed Effective 12/15/2002)
- 49906: AC->T or Docetaxel wkly or q3 wks node+ Br CA (E1199) (Closed Effective 01/08/2002)
- 49910: Post-mastectomy RT in St II, 1-3+ Nodes (S9927) (Closed Effective 6/15/2003)
|
CORRELATIVE SCIENCES FOR SOLID TUMORS: |
- 8861: BR2: CA15-3 (8541, 8743, 8782, 9344) (Closed Effective 09/01/1999)
- 8869: Flow Cytometry (8541, 8642, 8741, 8944) (Closed Effective 08/15/2001)
- 9484: Linkage Mol & Epid Br Ca Invest: Spec Registry (Closed Effective 09/01/1999)
- 9667: Bio Correl to Resp+ Surv in Colon Ca (E3293) (Closed Effective 02/15/2001)
- 9865: RER Stat and Outcme in Adj Tx for Colon Ca (Closed Effective 08/30/2002)
- 159902: Markers of Pleural Involvement in NSCLC (Closed Effective 09/30/2003)
- 159805: Lab Studies in Elderly Women w/Breast Ca (Closed Effective 07/15/2004)
|
GASTROINTESTINAL: |
- 9395: Peri-op therapy post Curative Resect (ECOG 1292) (Closed Effective 05/19/2000)
- 9481: FUDR, LV + Dex vs 5-FU, LV Colorectal Ca Hep Met (Closed Effective 12/29/2000)
- 9491: Eval of 5-FU/Leuc/Lev/XRT- Rectal (SWOG 9304) (Closed Effective 08/01/2000)
- 9581: Monoclonal Antibody 17-1A Stage B2 Colon Ca (Closed Effective 05/31/2002)
- 80001: Sentinel Node Staging of Colon Cancer (Limited Access) (Closed Effective 08/30/2002)
- 80002: Sphincter Preservation in Distal Rectal Cancer (Closed Effective 8/29/2003)
- 80004: STI 571 for Gastrointestinal Stromal Tumors (Closed Effective 09/01/2001)
- 89803: Adj CPT-11/5FU/Lv vs 5FU/Lv in St III/Hi Risk St (Closed Effective 05/15/2001)
|
GENITOURINARY: |
- 9682: Endorectal MRI of Localized Prostate Ca (Closed Effective 05/04/2001)
|
LEUKEMIA: |
- 9621: MDR-Modulation PSCT & IL-2 in AML < 60 Yrs (Closed Effective 03/31/2000)
- 9712: CLL: Fludarabine Followed by IDEC C2B8 (Closed Effective 01/31/2000)
- 9720: MDR-Modulation PSC-833 +/- IL-2 in AML &Mac179; 60 Yrs (Closed Effective 04/30/2002)
- 9790: Dex/Alpha IFN in AL Amyloidosis (SWOG S9628) (Closed Effective 03/15/2003)
- 19801: Ara-G in refractory/relapsed T-Cell ALL (Closed Effective 09/12/2001)
- 19802: ALL: Increased Doses of DNR & Ara-C (Closed Effective 01/05/2001)
- 19803: MDS: Random Trial of 2 Sched of Oral Topotecan (Closed Effective 05/31/2000)
- 19804: CML: HHT + Ara-C (Closed Effective 03/11/2002)
- 19805: CLL: Flavopiridol in Treated B-Cell CLL (Closed Effective 07/03/2002)
- 19901: CLL: Phase II Study of Fludarabine & Campath-1H (Closed Effective 02/28/2002)
|
LEUKEMIA CORRELATIVE SCIENCES: |
- 9662: Clonality in ABMT for Lymphoma (Closed Effective 01/31/2001)
|
LYMPHOMA: |
- 9251: NHL: Hi-Int Ctx for "J" category & L3 ALL
(Closed Effective 02/29/2000)
- 9391: HD:STNI vs STNI/Dox/VBL/Gd Risk (SWOG 9133)
(Closed Effective 04/20/2000)
- 9550: Low-Dose Interleukin-2 in AIDS-Lymphoma
(Closed Effective 08/31/99)
- 9551: 9AC in Relapsed NHL and Hodgkin’s Lymphoma
(Closed Effective 10/15/2000)
- 9650: Oral Etoposide in Relapsed NHL
(Closed Effective 10/15/2000)
- 9793: C2B8 Cons. Tx vs Obs. Post-Induc. w/CHOP NHL
(Closed Effective 07/12/2001)
- 50002: Ph. II Trial of Thalidomide for Rel/Ref Low Grade NHL
(Closed Effective 04/29/2004)
- 50103: EPOCH-R for Prev. Untreated Aggress B-Cell NHL
(Closed Effective 05/28/2004)
- 59804: Gemcitabine/Navelbine/Doxil in Refract/Rel HD
(Closed Effective 07/22/2003)
- 59902: Maintenance ANTI-CD20 vs. obs foll. induction (E1496)
(Closed Effective 05/02/2003)
- 59906: Dox/Topo in Refract/Rel Intermediate Grade NHL
(Closed Effective 08/04/2003)
- 59908: Allo Transplant for Mantle Cell Lymphoma
(Closed Effective 01/29/2003)
- 59910: EPOCH vs NHL-15 for Prev Untreated Aggressive NHL
(Closed Effective 02/15/2002)
|
MELANOMA: |
- 509801: Adj Ganglioside Vacc vs HiDose IFN for Hi Risk Melanoma (Closed Effective 10/15/1999)
|
PET: |
| |
RESPIRATORY: |
- 9631: Hi Dose Dox w GM-CSF + Dexraz for Malig Mesothelioma (Closed Effective 07/15/1997)
- 9733: CPT-11 for Malignant Mesothelioma (Closed Effective 01/29/1999)
- 9795: Rand Study of Adj Chemo w/Navel+Cis in NSCLC (Closed Effective 04/30/2001)
- 30101: ZD1839 in Malignant Mesothelioma (Closed Effective 03/14/2002)
- 39810: Herceptin for IIIB/IV, HER2 expressing, NSCLC (Closed Effective 07/19/2002)
|
|
|
| Back |
